Phase 1 Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Mogamulizumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 16 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Jul 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 16 Jun 2015 Status changed from planning to not yet recruiting, as reported by ClinicalTrials.gov record.